GlassScriptPhysician profile
Muneer Al Zoby
NPI 1083942999
$10,028.41
in general payments reported to CMS, 2019-2025
23 companies · $5,606 in 2025
The $5,606 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,162 · 2020: $219 · 2021: $556 · 2022: $366 · 2023: $358 · 2024: $1,761 · 2025: $5,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,678 · Food and Beverage: $1,625 · Travel and Lodging: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,678.25 |
| Food and Beverage | $1,624.79 |
| Travel and Lodging | $1,421.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,126.56 | 2024-2025 | |
| Glaxosmithkline, LLC. | $1,114.71 | 2019-2025 | Nucala, Trelegy Ellipta |
| Ethicon INC. | $469.82 | 2021-2023 | Monarch Platform |
| Astrazeneca Pharmaceuticals LP | $375.36 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $331.71 | 2021-2025 | Dupixent |
| Genzyme Corporation | $317.51 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $260.02 | 2022-2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $158.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.30 | 2019-2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $100.08 | 2019-2024 | |
| Genentech USA, INC. | $97.33 | 2019-2023 | Xolair |
| Covidien LP | $90.10 | 2019 | |
| Pulmonx Corporation | $89.80 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Sunovion Pharmaceuticals INC. | $79.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $74.52 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $41.41 | 2025 | Ohtuvayre |
| Medical Device Business Services, INC. | $40.40 | 2023 | Monarch |
| Grifols USA, LLC | $35.28 | 2019 | |
| Mylan Specialty L.P. | $20.70 | 2019 | |
| Paratek Pharmaceuticals, INC. | $19.71 | 2024 | Nuzyra |
| Conmed Corporation | $14.95 | 2019 | |
| Shire North American Group INC | $12.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muneer Al Zoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.